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Abstract: Ectromelia virus (ECTV) is an orthopoxvirus and the causative agent of mousepox.
Like other poxviruses such as variola virus (agent of smallpox), monkeypox virus and vaccinia virus
(the live vaccine for smallpox), ECTV promotes actin-nucleation at the surface of infected cells during
virus release. Homologs of the viral protein A36 mediate this function through phosphorylation of
one or two tyrosine residues that ultimately recruit the cellular Arp2/3 actin-nucleating complex.
A36 also functions in the intracellular trafficking of virus mediated by kinesin-1. Here, we describe
the generation of a recombinant ECTV that is specifically disrupted in actin-based motility allowing
us to examine the role of this transport step in vivo for the first time. We show that actin-based
motility has a critical role in promoting the release of virus from infected cells in vitro but plays a
minor role in virus spread in vivo. It is likely that loss of microtubule-dependent transport is a major
factor for the attenuation observed when A36R is deleted.
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1. Introduction
Ectromelia virus (ECTV) is an orthopoxvirus endemic to mice that has been used extensively as a
model for variola virus, the causative agent of smallpox [1]. In common with other orthopoxviruses,
ECTV is among a select group of bacterial and viral pathogens able to harness actin-nucleating activity
at the pathogen surface to promote their spread [2–4]. During infection of host cells, this activity
provides a propulsive force that can accelerate microbes through the host cytosol (Listeria monocytogenes;
Autographa californica multiple nucleopolyhedrovirus (AcMNPV)) or across the external surface
of the host plasma membrane (vaccinia virus (VACV); enteropathogenic Echerichia coli (EPEC)).
The contribution of actin-based motility to disease progression is difficult to assess in these complex
systems due to the pleiotropy of pathogen-encoded activators of actin polymerization and the lack of
availability of in vivo experimental models that faithfully reproduce endogenous infections.
Our understanding of the actin-based motility of orthopoxviruses is primarily derived from
VACV, the prototypal poxvirus used as the live vaccine to eradicate smallpox. However, actin-based
motility is conserved in the orthopoxvirus genus including variola virus, monkeypox virus, ECTV [5]
and further afield in the poxvirus family such myxoma virus and yaba-like disease virus (YLDV) [6,7].
Replication of VACV leads to production of two mature, infectious morphological variants: mature
virus (MV), with a single membrane derived from the endoplasmic reticulum; and wrapped virus
(WV), which possess one or two additional membranes of a trans-Golgi network (TGN) origin [8–10].
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Once WV are formed at a perinuclear site, they are translocated to the cell periphery by the action of
A36, F12, and E2, which collectively stabilize the microtubule motor complex, kinesin-1, at the viral
surface [11,12]. The cytoplasmic domain of A36 contains two Trp-Asp/Trp-Glu (WD/WE) motifs that
associate with kinesin-1 via tetratricopeptide repeats on kinesin light chain (KLC) isoform 1 [13,14].
F12 and E2 associate with KLC isoform 2, stabilizing the virus–kinesin-1 association [14]. At the cell
membrane, the outer WV membrane fuses with the plasma membrane resulting in cell-associated
extracellular virus particles that occupy membrane pits at the cell surface [8]. Tyrosine phosphorylation
of the cytoplasmic tail of A36 triggers a signaling cascade culminating in the recruitment and activation
of the Arp2/3 complex and robust actin polymerization [15,16]. The activity of the Arp2/3 complex
results in WV being released from their membrane pits, which are then readily visualized traversing
the cell surface on wakes of F-actin comets.
Actin-based motility of VACV can be ablated by the deletion of A36R (the gene that encodes A36)
or mutation of the critical tyrosine residues Y112 and Y132 (=VACV-A36YdF). As A36 is pleiotropic,
only A36YdF specifically disrupts actin-based motility while leaving the kinesin-1 recruitment function
intact [15]. Studies with VACV-A36YdF reveal a variety of defects at the cellular level in viral cell-to-cell
transmission. Cells infected with VACV-A36YdF do not form actin comets and plaques formed by
this virus are significantly reduced in size. Several mechanisms have been proposed to account
for how actin-based motility might lead to a defect in cell-to-cell transmission. When actin-based
motility localizes to the cell edge, virus-tipped membrane protrusions form that might facilitate
infection of adjacent cells [3]. Such a mechanism is thought to facilitate spread of the bacterium
Listeria monocytogenes, which, following vacuolar escape, spread throughout the cytoplasm on actin
comets and also form filopodia extensions laden with bacteria [17,18]. Actin-based motility also
promotes repulsion of super-infecting virions whereby early-stage infected cells repel extracellular
virus leading to faster spread in a monolayer [19]. Finally, it has been proposed that actin-based
motility may be required to disengage WV from the cell surface following exocytosis thereby releasing
free virus to the extracellular environment [15].
Infection of mice with VACV lacking A36 clearly reveal an important role in mediating virus
spread in an intact host as VACV-∆A36R exhibits a marked loss in virulence when administered in high
doses via the intranasal route [20]. The respective roles of actin-based motility and microtubule-based
transport that lead to the attenuation are unknown. The natural host of VACV is also unknown and
high titers of virus are required to infect experimental mice.
We have previously characterized the role of the VACV-A36R homolog in ECTV (ECTV-A36R)
and demonstrated that the key motifs that mediate kinesin-1 recruitment and actin-based motility
are conserved [2]. Susceptible BALB/c mice survive infection with high doses of ECTV-∆A36R but
were nonetheless able to raise protective immunity. We have now generated an ECTV recombinant
virus, ECTV-A36RY112F that specifically ablates actin-based motility. In VACV-A36R, both Y112 and
Y132 contribute to actin-based motility but only the Y112 is necessary and sufficient for robust
virus-associated actin nucleation [15,21]. Only the Y112 site is conserved in ECTV-A36R and,
as expected, cells infected with ECTV-A36RY112F do not exhibit actin-based motility of WV. Our analysis
of ECTV-Moscow (ECTV-Mos, the parental strain and ECTV reference strain, accession AF012825),
ECTV-∆A36R and ECTV-A36RY112F reveals that actin-based motility does not contribute significantly to
plaque size but does have a major role in promoting virus release from infected cells. When virus spread
was assayed in C57BL6 mice from subcutaneous injection, ECTV-A36RY112F was only mildly attenuated
in spread to the liver compared with the parental virus; a phenotype that was not exacerbated in
interferon γ deficient (IFN-γ−/−) or IFN-α/β receptor (R) (IFN-α/βR−/−) genetic backgrounds.
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2. Materials and Methods
2.1. Cells and Viruses
African green monkey kidney cells (BSC-1) and HeLa cells were maintained in Dulbecco’s
Modified Eagle’s Medium (DMEM; Invitrogen, Carlsbad, CA, USA) supplemented with 5% fetal
bovine serum (FBS), 292 mg/mL L-glutamine, 100 units/mL penicillin and 100 mg/mL streptomycin
(DMEM-FPSG) at 37 ◦C and 5% CO2. Viruses used in this study are ECTV-Mos (GenBank accession no.
AF012825), ECTV-∆A36 which has been described previously [2], from this virus the ECTV-A36Y112F
and ECTV-A36Res viruses were created. Briefly, plasmids containing recombination cassettes to replace
the mCherry fluorescent protein and guanosine phosphotransferase (GPT) selection markers were
made with the A36R gene either with the point mutation (for ECTV-A36Y112F) or parental sequence
(for ECTV-A36Res) and approximately 900 bp flanking regions of homologous ECTV genomic DNA
adjacent to the A36R locus. Constructs were transfected according to manufacturer’s instructions
(Lipofectamine 2000 reagent, Invitrogen) into HeLa cells infected with ECTV-∆A36 and homologous
recombination allowed to proceed for 24 h. Cells were scraped and the resulting virus screened by loss
of GPT resistance and fluorescence as described previously [22]. Viruses were purified by three rounds
of plaque purification, and insertion of the correct sequence was confirmed by sequencing.
2.2. Plaque Assays
BSC-1 cells were seeded in six-well plates and grown to confluence. Viruses were diluted in
serum free DMEM (SFM) and approximately 25 plaque forming units (PFU) was added to each
well. After incubation at 37 ◦C in 5% CO2 for 1 h, the cells were washed and overlaid with 1.5%
carboxymethyl cellulose (CMC) in minimal essential medium (MEM) containing 2.5% FBS, 292 mg/mL
L-glutamine, 100 units/mL penicillin and 100 mg/mL streptomycin. Cells were incubated for 6 days
post infection (days pi) and then the overlay removed and cells stained with 1% crystal violet in
methanol for visualization. Plaque diameter was measured by taking a straight line across the widest
point of the plaque using Image J software (version 2.0.0-rc-49/1.51a, National Institutes of Health,
Bethesda, MD, USA).
2.3. WV Release Assay
Six-well dishes were seeded with BSC-1 cells and incubated with virus (in triplicate) at an
multiplicity of infection (MOI) of 0.1 for 1 h. Cells were then washed twice with PBS and DMEM-FPSG
was added. The supernatants were collected at 24 h post infection (hpi), and spun at 10,000 rpm
for 10 min at 4 ◦C to remove cells and cellular debris. To quantify the infectious WV, plaque assays
of 10-fold serial dilutions of the supernatant were performed on BSC-1 cells as described above.
After 6 days, cells were stained with methanol/1% crystal violet and plaques enumerated. All WV
assays were performed on at least three separate occasions.
2.4. Immunofluorescence Assay
Cells were grown on glass coverslips, infected with virus, and fixed at 16 or 24 hpi with 3%
paraformaldehyde (PFA) in cytoskeletal buffer (CB) [10 mM 2-(N-morpholino) ethanesulfonic acid
(MES) buffer, 0.15 M NaCl, 5 mM ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic
acid (EGTA), 5 mM MgCl2, 50 mM glucose, pH 6.1] for 10 min at room temperature or ice-cold
100% methanol for 15 min. Cells were blocked in blocking buffer (1% bovine serum albumin (BSA)
and 2% FBS in CB) for 20 min and then incubated for 40 min with suitable primary antibodies
diluted in blocking buffer. Primary antibodies used in this study were: anti-A36-Y112 [2] and
anti-B5 [23]. Fluorescent chemicals used were: Alexa Fluor 568-phalloidin (Invitrogen) and DAPI
(4′,6-diamidino-2-phenylindole; Sigma-Aldrich, St. Louis, MO, USA). After three washes with PBS,
secondary antibodies (Alexa Fluor 488-conjugated goat anti-rat IgG and Alexa Fluor 568-conjugated
goat anti-rabbit IgG; Invitrogen) diluted in blocking buffer were applied to cells for 20 min.
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The coverslips were mounted on a glass slide with 0.3–1% (w/v) p-phenylenediamine (Sigma-Aldrich)
in Mowiol mounting medium (10% (w/v) polyvinyl alcohol 4–88 (Sigma-Aldrich), 25% (w/v) glycerol,
0.1 M Tris, pH 8.5). Images were captured on an Olympus BX51 microscope (Tokyo, Japan) with a
reflected fluorescence system using AnalySIS LS Starter (Olympus Soft Imaging Systems, ver. 2.8).
2.5. Immunoblot Analysis
BSC-1 cells were infected with virus at an MOI of 1 for 24 h. Infected cells were harvested
in sodium dodecyl sulfate (SDS)-reducing sample buffer (62.5 mM Tris-HCl, 0.25 M glycerol, 2%
SDS, 0.01% (w/v) bromophenol blue, 12.5% (v/v) β-mercaptoethanol) and boiled at 95 ◦C for 5 min.
Proteins were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) (resolving gel of
10% acrylamide-Bis solution (37.5:1), 0.375 M Tris-HCl, pH 8.8, 0.1% (w/v) SDS, 0.1% ammonium
persulfate (APS), and 0.1% N,N,N=,N=-tetramethylethylenediamine (TEMED); stacking gel of 4% to
30% acrylamide-Bis solution (37.5:1), 0.375 M Tris-HCl, pH 6.8, 0.1% (w/v) SDS, 0.1% APS, and 0.1%
TEMED). Resolved proteins from SDS-PAGE were transferred to nitrocellulose membranes (Hybond-C
Extra; Amersham Biosciences, Little Chalfont, UK) and probed with primary antibodies diluted
in PBST-milk (5% (w/v) skim milk in PBS with 0.1% Tween 20). Primary antibodies used in this
study were anti-A36-Y112 [2], anti-L1 (NR-631, BEI Resources, Manassas, VA, USA), and anti-β-actin
(AC-74, Sigma-Aldrich). The membrane was washed three times in PBST-milk and probed with
secondary antibodies conjugated with horseradish peroxidase (HRP) (goat anti-mouse IgG HRP and
goat anti-rabbit IgG HRP; Santa Cruz Biotechnology, Dallas, TX, USA). Immunoreactive protein bands
were visualized with ECL Western blotting reagent (GE Health, Little Chalfont, UK).
2.6. Mouse Experiments
C57BL/6 wild-type, C57BL/6 IFN-γ−/− and C57BL/6 IFN-α/β receptor (R)−/− (IFN-α/βR−/−)
mice were challenged by injection subcutaneously in the right hind leg (hock) with 103 PFU virus and
sacrificed at 5 days pi. Viral loads in livers, spleens, and lymph nodes were quantified by viral plaque
assay on BSC-1 cell monolayers as described above and are expressed as log10 PFU per gram of tissue
or per popliteal lymph node.
2.7. Ethics Statement
This study was performed in accordance with the recommendations in the Australian code
of practice for the care and use of animals for scientific purposes and the Australian National
Health and Medical Research Council Guidelines and Policies on Animal Ethics. The Australian
National University Animal Ethics and Experimentation Committee approved all animal experiments
(Protocol Numbers: J.IG.75.09 and A2012/041). Tribromoethanol (Avertin, Millipore Sigma, St. Louis,
MO, USA) was used as the anesthetic (200–240 mg/kg body weight) given via intra-peritoneal injection
prior to infection with virus. The respiration rate of the animals was monitored during anesthesia and
recovery took place upon a warm table. Animals were euthanized by cervical dislocation. The animal
ethics approval did not allow for mortality experiments and for all mice to be euthanized in the
event that 20% of the mice succumbed to disease. For these reasons, all mice were euthanized at
Day 5 post-infection.
3. Results
3.1. Generation of ECTV-A36Y112F
To assess the role of actin-based transport in ECTV, four viruses were used. The parental
ECTV-Mos shares a high level of sequence identity with VACV Western Reserve (VACV-WR), with the
exception of a large truncation at the C-terminal that removes three Asn-Pro-Phe (NPF) motifs that
recruit intersectin-1 [24]. Although the WD/WE motifs that mediate kinesin-1 binding are intact,
of the two critical tyrosines in VACV-WR at positions 112 and 132, only the first, Y112, is present in
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ECTV-Mos (Figure 1A). The A36R gene was deleted in ECTV-Mos by replacing the gene with selectable
(GPT resistance) and screenable (mCherry fluorescence) markers. This created the ∆A36 virus, which is
deficient in both microtubule transport and actin-based motility [2]. From an ECTV-∆A36 background,
ECTV-A36Res and ECTV-A36RY112F were made by rescue of the small plaque phenotype. ECTV-A36Res
restored a wild type copy of A36R and was expected to fully restore function of virus. ECTV-A36Y112F
carries a Y112F substitution, which was predicted to specifically disrupt the actin-based motility
function of A36R while leaving other functions intact (Figure 1B). Viruses were then sequenced at the
A36R gene by Sanger sequencing to confirm the mutation (Figure 1C).
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To analyze A36 expression (the protein encoded by the A36R gene), cells were infected with
ECTV-Mos, ECTV-∆A36, ECTV-A36Y112F and ECTV-A36Res and the lysates collected at 48 h post
infection (hpi). A36 was detected in ECTV-Mos, ECTV-A36Y112F and ECTV-A36Res at the expected
size of 34 kDa (Figure 2A). We therefore successfully confirmed ECTV-A36Res restores normal
levels of A36 expression and that the Y112F mutation does not grossly disrupt A36 stability or
mobility. We further analyzed A36 localization by immunofluorescence assay. Cells were infected with
ECTV-Mos, ECTV-∆A36, ECTV-A36Y112F and ECTV-A36Res and fixed at 16 hpi. Cells were stained with
antibodies against A36 and known WV protein B5. As expected, A36 colocalized with B5 in ECTV-Mos,
ECTV-A36Y112F and ECTV-A36Res, but not in ECTV-∆A36, where it is only detected at background
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levels (Figure 2B). This confirms that both ECTV-A36Y112F and ECTV-A36Res viruses restore normal
A36 expression and localization.
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3.2. A36R Is Required for ECTV Actin-Based Motility and Virus Release
We then tested the ability of ECTV-A36Y112F to undergo actin-based motility. HeLa cells
were infected with ECTV-Mos, ECTV-∆A36, ECTV-A36Y112F and ECTV-A36Res and fixed at 16 hpi,
then stained with anti-B5R to visualize wrapped virus and phalloidin to visualize F-actin. Actin-based
motility is evident in ECTV-infected cells by the association of WV with comets of F-actin, which is
absent when A36R has been deleted (Figure 3A). Although small accumulations of F-actin could
occasionally be found in association with WV in ECTV-A36Y112F-infected cells, no comets were
observed, which is consistent with an essential role for Y112F in promoting actin-based motility
of ECTV. We have previously shown that release of WV by VACV is strongly attenuated by the Y112F
mutation (and also by the Y112F/Y132F double mutation, VACV-A36YdF) [15]. In line with these
results, virus release by ECTV is also dependent on actin-based motility as ECTV-A36Y112F-infected
cells displayed a dramatic (15-fold) reduction in WV release (Figure 3B). Wild type ECTV A36R fully
restored actin-based motility and WV release (Figure 3A,B).
3.3. Actin-Based Motility Does Not Contribute to Cell-to-Cell Spread of ECTV
To determine the effect of actin-based motility on cell-to-cell spread of ECTV, plaque assays were
performed in BSC-1 cells. Cells were infected with ECTV-Mos, ECTV-∆A36, ECTV-A36Y112F and
ECTV-A36Res and plaques allowed to develop over six days. There were no significant differences
in plaque size between ECTV-Mos, ECTV-A36Y112F and ECTV-A36Res although we were able to
replicate the small plaque phenotype of ECTV-∆A36 (Figure 4A,B). This is somewhat surprising as
VACV-A36YdF exhibits a significant reduction in cell-to-cell spread [12]. Thus, cell-to-cell spread of
ECTV is primarily mediated by microtubule-dependent transport with actin-based motility playing a
non-significant role.
3.4. Actin-Based Motility Plays a Minor Role in ECTV Spread In Vivo
To assess the consequences of loss of microtubule transport and actin-based motility we next
examined the ability of ECTV to spread in vivo. ECTV-resistant C57BL/6 mice were infected
subcutaneously in the right hind leg with 103 PFU virus and sacrificed five days pi, and viral
dissemination to three distal sites (popliteal lymph nodes, liver and spleen) was quantified. To gain
further insight into the effects of defective viral transport in vivo, three subsets of mice were used, either
WT, IFN-γ−/− or IFN-α/βR−/−. Viral dissemination to the lymph nodes was reduced significantly
by three orders of magnitude in ∆A36 in WT mice (Figure 5A). However, deletion or mutation of
A36 had no discernible effects on viral spread in IFN-γ−/− or IFN-α/βR−/− mice (Figure 5B,C),
with ECTV readily disseminating to the lymph nodes in these mice. In contrast, viral spread to the
liver was dramatically reduced in ECTV-∆A36 and significantly reduced in ECTV A36Y112F-infected
mice (Figure 5D–F). In all murine backgrounds, the change in viral dissemination is greatest for
ECTV-∆A36 infections, while the spread of ECTV-A36Y112F was reduced to a lesser extent. In the
spleen, dissemination of ECTV-∆A36 was significantly reduced but a phenotype for ECTV-A36Y112F
was only observed in WT mice (Figure 5G–I). These results suggest that defects in actin-based motility
have a minor, but detectable, role in mediating spread of ECTV in vivo but that the primary basis for
the attenuation of ECTV-∆A36 is loss of microtubule-based transport.
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in BSC-1 monolayers infected with serially diluted virus and overlaid with 1.5% carboxymethyl
cellulose in minimal essential medium (CMC-MEM). At six days pi, plaques were visualized by: phase
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(n = 30). (**** p < 0.0001; ns, non-significant; unpaired t-test).
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mice with WT, IFN-γ−/− or IFN-α/βR−/− genetic backgrounds ere infected subcutaneously
in the right hind paw with 103 PFU virus and sacrificed at five days pi, viral dissemination to
(A–C) the popliteal lymph nodes; (D–F) the liver and (G–I) the spleen, was quantified by plaque
assay. (**** p 0.0001; *** p < 0.001; ** p < 0.01; * p < 0.05; one-way ANOVA).
4. Discussion
Actin-based otility is a highly conserved feature of the orthopoxvirus genus. Virally
induced actin nucleation has been demonstrated for VACV, ECTV, variola and monkeypox
viruses [2,5,16,25–27], and is predicted to be a feature of replication in other members of this genus
based on the conservation of the A36R gene, with a sequence identity between 81% and 100% for all
published sequences [28]. The A36 protein family includes two tyrosines embedded in a Src-family
kinase substrate motif, with the exception of ECTV-A36 that contains only the N-terminal tyrosine [29].
Our results confirm that actin-based motility in ECTV is mediated by the A36 protein, and further
demonstrate that the 112 tyrosine is the critical residue required for actin nucleation. This is as expected,
but represents only the second instance where the basis for actin-based motility has been mapped
genetically in a poxvirus [15,16,25,26]. Within the wider Poxviridae family, actin-based motility has
been observed in myxomavirus and YLDV [6,7]. YLDV, a member of the yatapoxvirus genus, has been
observed to form virus-associated actin tails during infection, yet lacks an obvious A36R homolog [7,30].
It was found that YLDV encodes a functional ortholog of A36R, termed YL126, which appears to
promote actin-based motility. Although containing less than 15% amino acid identity to A36, it is
found in an analogous genomic loci (YL124R and YL127R are orthologs of VACV A35R and A37R,
respectively [28,30]), contains five tyrosines that are able to be phosphorylated, and can furthermore
restore actin-based motility in ∆A36 VACV infected cells [28]. YL126 homologs have been identified
in the other members of the yatapoxvirus family as well as myxomavirus, and in members of the
carpripoxvirus, leporipoxvirus and suipoxvirus families [28]. The conservation of actin-based motility
across diverse poxviruses suggests an important role in viral spread across a range of hosts.
Our results demonstrate that, while release of ECTV WV into the extracellular media is strongly
defective in the absence of actin-based motility, loss of this motility has only minor consequences
in vivo for the pathogenesis of ECTV. In contrast, the loss of the microtubule-based transport function
Viruses 2018, 10, 111 11 of 14
of A36 results in a significant reduction of viral spread both in vitro and in vivo. We propose that
the critical function of A36, in terms of virulence in vivo, lies in translocating WV to the cell surface.
Ablation of actin-based motility did not significantly affect the cell-to-cell spread of ECTV in vitro.
This result was somewhat unexpected given that in VACV a mutation in actin-based motility via
deletion of one or both tyrosines (VACV-A36Y112F or VACV-A36YdF) does result in a reduction of
cell-to-cell spread [15]. This suggests that though highly conserved, there is some variation among
poxviruses in their requirement for actin-based motility during their replication cycle. A plaque
assay quantitates the cell-to-cell spread of virus but not the contribution of spread of WV through
the extracellular media, which is inhibited by the overlay. For example, treating VACV with the Abl
kinase inhibitor imatinib causes substantial reduction in release of WV from infected cells, yet does
not lead to a significant reduction in plaque size [31]. A possible explanation for why ablation of
actin-based motility in VACV and ECTV results in different outcomes for cell-to-cell spread may be
due to the repulsion of super-infecting virions. This process allows viral spread to occur faster than
the rate of replication dynamics by means of extracellular WV being blocked from entry to early
infected cells via cell surface signaling, promoting their spread to uninfected cells via actin-based
motility [19,32]. Repulsion requires the early expression of A36 and A33 at the surface of infected
cells and the expression of B5 on the surface of the repelled WV [19,32]. The absence of an observable
defect in ECTV-A36Y112F plaques could be attributable to super-repulsion not playing a role in ECTV
spread. In this case, the function of actin-based motility may lie solely in promoting release. We have
previously suggested that actin-based motility in poxviruses may have evolved to promote WV
release; a mechanism later coopted for super-repulsion. Although our data would appear to support
this hypothesis, ECTV-A36R is still an early expressed gene. Alternatively, the small plaque size
of ECTV may mask the contribution of actin-based motility rendering the assay less sensitive to
small differences.
Our results demonstrate only a minor role for actin-based motility for virus spread in vivo.
While we observed a detectable reduction in viral titers in distal organs associated with ECTV-A36Y112F,
this was negligible in comparison to the effect of deleting A36. Our data also establish that intact IFN-γ
and IFN-α/β signaling are critical for A36 function, particularly for virus dissemination to the lymph
node, but less so for dissemination to the liver and spleen. While our ethics approval did not allow for
mortality experiments, based on the viral load in liver and spleen of the IFN-γ−/− and IFN-α/βR−/−
mice at Day 5, and based on our experience with the mousepox model, we predict that gene knock-out
mice challenged with ECTV-∆A36 would have survived, whereas those challenged with ECTV-Mos,
ECTV-A36Y112F or ECTV-A36Res would have all succumbed to mousepox. We speculate that if orders
of magnitude lower doses of virus were used, we may have seen more significant differences between
ECTV-Mos and ECTV-A36Y112F or between ECTV-∆A36 and ECTV-A36Y112F. We conclude that
viral release mediated by actin-based motility is not a major determinant to the virulence of ECTV.
There is little consensus in the literature as to how WV release correlates to poxvirus virulence in vivo.
While poxvirus WV release is complex and not fully characterized, several mutations that increase
release have been identified. However, these are typically, but not exclusively, associated with a
reduction in cell-to-cell spread as measured by plaque assay and these viruses are attenuated in vivo
(for example, VACV-B5P189S; [33–37]. The IHD-J strain of VACV carries a mutation that results in
viral release 40 times higher than WR but forms normal sized plaques [33]. This strain displays lower
mortality than WR in a murine infection model; however, when compared to other strains of VACV,
there was a positive correlation of WV release with virulence. This suggests that WR, which produces
low numbers of WV, may be the exception rather than the rule [38]. Conversely, a comparative study of
variola virus strains found a negative correlation between WV release and virulence [39]. While its role
in virulence remains cryptic, there are suggestions that high WV release may have a role in increasing
the transmission of virus between individuals [38–40]. Future studies may examine this potential role
for WV release, a context that is largely mechanistically uncharacterized.
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Actin-based motility is utilized not only by poxviruses but also by a wide range of bacterial
pathogens including species of Listeria, Rickettsia, Shigella, Mycobacteria, Burkholderia, and EPEC [41,42].
Understanding the molecular basis for actin-based motility can provide clues about both disease
pathogenesis and cellular biology. Indeed the study of Listeria monocytogenes motility was key to
identifying the Arp2/3 complex as an inducer of actin nucleation [18]. In many cases, actin-based
motility of pathogens is difficult to study in whole animal models due to multiple or unclear paths of
activation, activators with multiple functions, or lack of an endogenous disease model. Many of these
bacteria are human pathogens, and study of their interaction with host cellular systems is hindered by
species-specific interactions in small animal models. For example, multiple species-specific barriers
exist when mice are infected with L. monocytogenes, such as the internalin–E-cadherin engagement
during entry [17]. ActA, the nucleator of L. monocytogenes, is also highly pleiotropic with a role in
the aggregation of bacteria [43]. In ECTV, we have an opportunity to study a pathogen in its natural
host, whereby we can manipulate not only the gene responsible for actin-based motility but also
ablate actin-based motility with the substitution of a single amino acid. Our understanding of how
actin-based motility of ECTV affects the spread of virus in vivo may provide clues about disease
progression among poxviruses and other pathogens, and help build a more complete picture of
cytoskeletal remodelling by microbes.
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